Prognostic impact of baseline tumor size (BTS) on survival outcomes in patients (pts) with untreated advanced nonsmall cell lung cancer (NSCLC), PD-L1 ≥50%, treated with pembrolizumab alone

被引：0

作者：

Bureau, M. ^{[1
]}

Chatelier, T. ^{[2
]}

Perennec, T. ^{[1
]}

Goronflot, T. ^{[3
]}

Greilsamer, C. ^{[4
]}

Chene, A-L. ^{[5
]}

Affi, R. ^{[1
]}

Bennouna, J. ^{[1
]}

Pons-Tostivint, E. ^{[1
]}

机构：

[1] Univ Hosp Nantes, Dept Pneumol, Thorac Med Oncol Funct Unit, Nantes, France

[2] Clin Mutualiste Estuaire, Med Oncol, St Nazaire, France

[3] Univ Hosp Nantes, Biostat Dept, Nantes, France

[4] Hosp La Roche Sur Yon, Med Oncol, La Roche Sur Yon, France

[5] Univ Hosp Nantes, Pneumol Dept, Nantes, France

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1897

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1295P

引用

页码：S1004 / S1004

页数：1

共 50 条

[11] COST EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB MONOTHERAPY IN ADVANCED PD-L1 ≥50% NON-SMALL CELL LUNG CANCER (NSCLC) IN THE IRISH SETTING
Chu, R.
Vegas, A.
Gorry, C.
Power, D.
VALUE IN HEALTH, 2022, 25 (01) : S61 - S61
[12] Impact of PD-L1 Expression on the Overall Survival of Patients With Non-small Cell Lung Cancer Treated With Single-agent Pembrolizumab
Svaton, Martin
Knetki-Wroblewska, Magdalena
Tabor, Sylwia
Domecky, Petr
Venclicek, Ondrej
Krejci, Jana
Drosslerova, Marie
Hrnciarik, Michal
Hricisak, Daniel
Bejckova, Alzbeta
Fischer, Ondrej
Vitkova, Martina
Krzakowski, Maciej
IN VIVO, 2024, 38 (05): : 2434 - 2440
[13] Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy
Hopkins, Ashley M.
Wagner, Jordan
Kichenadasse, Ganessan
Modi, Natansh
Rowland, Andrew
Sorich, Michael J.
INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (11) : 3085 - 3089
[14] Early Changes in Tumor Size in Patients Treated for Advanced Stage Nonsmall Cell Lung Cancer Do Not Correlate With Survival
Birchard, Katherine R.
Hoang, Jenny K.
Herndon, James E., Jr.
Patz, Edward F., Jr.
CANCER, 2009, 115 (03) : 581 - 586
[15] Early Changes in Tumor Size in Patients Treated for Advanced Stage Nonsmall Cell Lung Cancer Do Not Correlate With Survival
Oxnard, Geoffrey R.
Schwartz, Lawrence H.
CANCER, 2010, 116 (06) : 1615 - 1615
[16] Impact of age on outcomes with PD-(L)1 blockade in patients (Pts) with non-small cell lung cancer (NSCLC).
Lichtenstein, Morgan
Nipp, Ryan David
Goodwin, Kelly
Anderson, Danyon
Newcomb, Richard
Gainor, Justin F.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[17] Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
Incorvaia, Lorena
Fanale, Daniele
Badalamenti, Giuseppe
Barraco, Nadia
Bono, Marco
Corsini, Lidia Rita
Galvano, Antonio
Gristina, Valerio
Listi, Angela
Vieni, Salvatore
Gori, Stefania
Bazan, Viviana
Russo, Antonio
ADVANCES IN THERAPY, 2019, 36 (10) : 2600 - 2617
[18] Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
Lorena Incorvaia
Daniele Fanale
Giuseppe Badalamenti
Nadia Barraco
Marco Bono
Lidia Rita Corsini
Antonio Galvano
Valerio Gristina
Angela Listì
Salvatore Vieni
Stefania Gori
Viviana Bazan
Antonio Russo
Advances in Therapy, 2019, 36 : 2600 - 2617
[19] PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy
Sorensen, Steffen Filskov
Zhou, Wei
Dolled-Filhart, Marisa
Georgsen, Jeanette Baehr
Wang, Zhen
Emancipator, Kenneth
Wu, Dianna
Busch-Sorensen, Michael
Meldgaard, Peter
Hager, Henrik
TRANSLATIONAL ONCOLOGY, 2016, 9 (01): : 64 - 69
[20] PD-L1 expression and survival in patients with non-small cell lung cancer (NSCLC) in Korea
Sun, Jong-Mu
Zhou, Wei
Choi, Yoon-La
Choi, So-Jung
Kim, Se Eun
Wang, Zhen
Dolled-Filhart, Marisa
Emancipator, Kenneth
Weiner, Russell
Park, Minjin
Kim, Hong Kwan
Choi, Yong Soo
Shim, Young Mog
Kim, Jhingook
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

← 1 2 3 4 5 →